4D pharma plc (AIM: DDDD), a pharmaceutical company involved in the development of Live Biotherapeutics, announced yesterday that it has named Ed Baracchini, PhD, and Professor Axel Glasmacher, MD, as independent non-executive directors with immediate effect.
Ed Baracchini, PhD, was earlier the chief business officer at Xencor Inc where he led strategic alliances and licensing. During his time at Xencor he negotiated license agreements with Novartis, Novo Nordisk and Amgen among numerous others. Prior to that he served as SVP Business Development for Metabasis Therapeutics.
Professor Dr med Axel Glasmacher was until recently senior vice president and head of the Global Clinical Research and Development Hematology Oncology at Celgene, where he has worked in various global roles for more than ten years. Prior to Celgene, Professor Glasmacher worked within the fields of haematology-oncology at the University Hospital in Bonn.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business